WO2017077551A3 - An amorphous nintedanib esylate and solid dispersion thereof - Google Patents
An amorphous nintedanib esylate and solid dispersion thereof Download PDFInfo
- Publication number
- WO2017077551A3 WO2017077551A3 PCT/IN2016/050378 IN2016050378W WO2017077551A3 WO 2017077551 A3 WO2017077551 A3 WO 2017077551A3 IN 2016050378 W IN2016050378 W IN 2016050378W WO 2017077551 A3 WO2017077551 A3 WO 2017077551A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amorphous
- nintedanib
- solid dispersion
- nintedanib esylate
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Abstract
Nintedanib base polymorphic forms and processes for preparing the same. A process for the purification of nintedanib base is disclosed. An amorphous form of nintedanib and process for the preparation of the same are also disclosed. A solid dispersion of amorphous nintedanib with pharmaceutically acceptable excipients and processes for the preparation of the same are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5942CH2015 | 2015-11-03 | ||
IN5942/CHE/2015 | 2015-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017077551A2 WO2017077551A2 (en) | 2017-05-11 |
WO2017077551A3 true WO2017077551A3 (en) | 2017-06-15 |
Family
ID=57838443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2016/050378 WO2017077551A2 (en) | 2015-11-03 | 2016-11-02 | An amorphous nintedanib esylate and solid dispersion thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017077551A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3597636A4 (en) | 2017-03-14 | 2020-10-21 | Allgenesis Biotherapeutics Inc. | Crystal forms of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone |
JP2024016309A (en) * | 2020-12-21 | 2024-02-07 | トーアエイヨー株式会社 | solid dispersion |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004013099A1 (en) * | 2002-07-24 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
WO2009071523A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an indolinone derivative |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
UY31506A1 (en) | 2007-12-03 | 2009-08-03 | INDOLINONE DERIVATIVES AND PROCEDURE FOR PREPARATION |
-
2016
- 2016-11-02 WO PCT/IN2016/050378 patent/WO2017077551A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004013099A1 (en) * | 2002-07-24 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
WO2009071523A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an indolinone derivative |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "New crystalline forms of methyl-(3Z)-3-[({4-[N-methyl-2-(4-methyl-1-piperazinyl)acetamido]phenyl}-amino)(phenyl)methylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate (IPCOM000210964D)", IP.COM JOURNAL, 19 September 2011 (2011-09-19), XP002767764 * |
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, vol. 198, 1 January 1998 (1998-01-01), SPRINGER, BERLIN, DE, pages 163 - 208, XP008166276, ISSN: 0340-1022 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017077551A2 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015110897A3 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
WO2015166379A3 (en) | Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts | |
WO2015145415A3 (en) | Ibrutinib solid forms and production process therefor | |
EP3682982A4 (en) | Manufacturing process for large annular forged piece | |
WO2016125191A3 (en) | Processes for the preparation of vortioxetine hydrobromide | |
WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
WO2016125192A3 (en) | Processes for the preparation of dolute-gravir | |
WO2018069941A3 (en) | Polymorphic forms of venetoclax | |
WO2018029711A3 (en) | Process for the preparation of venetoclax | |
EP3630738A4 (en) | Process for the production of ozanimod | |
WO2014125506A3 (en) | A process for the preparation of ivacaftor and its intermediates | |
EP3694499A4 (en) | Novel process for the preparation of lifitegrast | |
EP3297678A4 (en) | An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | |
WO2015159275A3 (en) | An improved process for the preparation of rifamycin derivatives | |
WO2016125190A3 (en) | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof | |
WO2016108206A3 (en) | Processes for preparation of idelalisib and intermediates thereof | |
WO2015068175A3 (en) | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | |
WO2016024286A3 (en) | An improved process for synthesis of lenalidomide | |
IL270177B (en) | Process for the preparation of deuterated ethanol from d2 | |
EP3728241A4 (en) | Process for the preparation of opicapone and intermediates thereof | |
WO2019130252A3 (en) | Methods and intermediates for preparing deutetrabenazine | |
WO2017077551A3 (en) | An amorphous nintedanib esylate and solid dispersion thereof | |
WO2014016660A3 (en) | Process for preparation of darunavir | |
EP3565552A4 (en) | An improved process for the preparation of rivaroxaban involving novel intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16828788 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16828788 Country of ref document: EP Kind code of ref document: A2 |